Bavarian Nordic abandons Covid booster after data show it's not as effective against new variants
Bavarian Nordic is abandoning its Covid-19 booster vaccine after Phase III results — even though it did hit the primary endpoint of the study — because it’s not as effective against newer variants of the virus.
The capsid virus-like particle (cVLP) based booster, called ABNCoV2, did lower the levels of neutralizing antibodies against the original SARS-CoV-2 variant. But even if the data found that it was non-inferior to the participants in the study who were vaccinated with Pfizer and BioNTech’s Comirnaty, it was for a variant that is “no longer the primary concern,” Bavarian said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.